← Back to Screener
Microbot Medical, Inc. Common Stock (MBOT)
Price$2.39
Favorite Metrics
Price vs S&P 500 (26W)-31.34%
Price vs S&P 500 (4W)-15.29%
Market Capitalization$160.51M
All Metrics
Book Value / Share (Quarterly)$1.15
P/TBV (Annual)11.71x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-6.10%
Cash Flow / Share (Quarterly)$-0.20
Price vs S&P 500 (YTD)16.86%
Gross Margin (TTM)75.23%
Net Profit Margin (TTM)-3886.60%
EPS (TTM)$-0.31
10-Day Avg Trading Volume1.70M
EPS Excl Extra (TTM)$-0.31
Revenue Growth (5Y)0.40%
EPS (Annual)$-0.29
ROI (Annual)-16.95%
Gross Margin (Annual)82.79%
Net Profit Margin (5Y Avg)-5624.44%
Cash / Share (Quarterly)$1.17
Revenue Growth QoQ (YoY)-50.00%
ROA (Last FY)-16.12%
EBITD / Share (TTM)$-0.31
ROE (5Y Avg)-167.81%
Operating Margin (TTM)-4163.92%
Cash Flow / Share (Annual)$-0.20
P/B Ratio2.07x
P/B Ratio (Quarterly)1.73x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)161.44x
Net Interest Coverage (TTM)-113.63x
ROA (TTM)-23.12%
EV / EBITDA (TTM)6.16x
EPS Incl Extra (Annual)$-0.29
Current Ratio (Annual)23.33x
Quick Ratio (Quarterly)23.04x
3-Month Avg Trading Volume1.93M
52-Week Price Return4.82%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$97.43
P/S Ratio (Annual)158.92x
Asset Turnover (Annual)0.03x
52-Week High$4.67
Operating Margin (5Y Avg)-5730.35%
EPS Excl Extra (Annual)$-0.29
CapEx CAGR (5Y)-7.79%
Tangible BV CAGR (5Y)-27.14%
26-Week Price Return-27.36%
Quick Ratio (Annual)23.04x
13-Week Price Return12.21%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)23.33x
Enterprise Value$156.596
Revenue / Share Growth (5Y)-23.91%
Asset Turnover (TTM)0.03x
Book Value / Share Growth (5Y)-19.51%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3194.06%
Cash / Share (Annual)$1.17
3-Month Return Std Dev80.05%
Net Income / Employee (TTM)$-1
ROE (Last FY)-16.95%
Net Interest Coverage (Annual)-113.00x
EPS Basic Excl Extra (Annual)$-0.29
P/FCF (TTM)6.69x
Receivables Turnover (TTM)27.71x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.31
Receivables Turnover (Annual)7.48x
ROI (TTM)-24.44%
P/S Ratio (TTM)165.47x
Pretax Margin (5Y Avg)-5540.77%
Revenue / Share (Annual)$25.25
Tangible BV / Share (Annual)$137.75
Price vs S&P 500 (52W)-25.01%
Year-to-Date Return19.50%
5-Day Price Return-3.63%
EPS Normalized (Annual)$-0.29
ROA (5Y Avg)-108.07%
Net Profit Margin (Annual)-3241.58%
Month-to-Date Return-0.83%
Cash Flow / Share (TTM)$-1.14
EBITD / Share (Annual)$-0.31
Operating Margin (Annual)-3301.98%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-167.81%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.31
P/TBV (Quarterly)6.38x
P/B Ratio (Annual)1.73x
Pretax Margin (TTM)-3872.16%
Book Value / Share (Annual)$1.15
Price vs S&P 500 (13W)11.52%
Beta1.19x
Revenue / Share (TTM)$13.86
ROE (TTM)-24.44%
52-Week Low$1.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.11
4.11
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
MBOTMicrobot Medical, Inc. Common Stock | 165.47x | 0.40% | 75.23% | -4163.92% | $2.39 |
SYKStryker Corporation | 5.15x | 11.84% | 64.57% | 19.43% | $338.38 |
BSXBoston Scientific Corp. | 4.76x | 15.16% | 69.01% | 18.00% | $63.42 |
MMM3M Company | 3.18x | -4.97% | 39.92% | 18.55% | $150.55 |
MDLNMedline Inc. Class A common stock | 2.21x | — | 26.44% | 7.78% | $46.94 |
BDXBecton, Dickinson and Co. | 2.01x | 6.32% | 46.42% | 12.15% | $154.82 |
RMDResMed Inc. | 6.06x | 11.72% | 60.85% | 33.70% | $224.72 |
DXCMDexCom, Inc. | 5.23x | 19.33% | 62.09% | 19.56% | $61.23 |
WSTWest Pharmaceutical Services, Inc. | 6.22x | 7.44% | 35.91% | 19.03% | $269.81 |
PODDInsulet Corporation | 5.31x | 24.53% | 71.63% | 12.92% | $201.47 |
PENPenumbra, Inc. | 9.31x | 20.16% | 67.14% | 13.48% | $331.47 |
About
Microbot Medical develops robotic solutions for endovascular procedures, a minimally invasive approach to treating vascular conditions. The company's LIBERTY Endovascular Robotic System is a single-use, remotely operated platform designed to enhance precision and provider safety in vascular interventions. With a robust intellectual property portfolio, Microbot aims to establish a new standard in endovascular care delivery.